X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs NOVARTIS - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA NOVARTIS GSK PHARMA/
NOVARTIS
 
P/E (TTM) x 67.4 295.9 22.8% View Chart
P/BV x 11.8 25.2 46.9% View Chart
Dividend Yield % 1.1 1.4 74.0%  

Financials

 GSK PHARMA   NOVARTIS
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
NOVARTIS
Mar-17
GSK PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs3,838855 448.9%   
Low Rs2,637666 396.2%   
Sales per share (Unadj.) Rs354.2219.0 161.7%  
Earnings per share (Unadj.) Rs39.819.1 208.2%  
Cash flow per share (Unadj.) Rs42.920.3 211.2%  
Dividends per share (Unadj.) Rs30.0010.00 300.0%  
Dividend yield (eoy) %0.91.3 70.5%  
Book value per share (Unadj.) Rs236.9307.0 77.2%  
Shares outstanding (eoy) m84.7029.96 282.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.13.5 263.3%   
Avg P/E ratio x81.439.8 204.5%  
P/CF ratio (eoy) x75.537.5 201.6%  
Price / Book Value ratio x13.72.5 551.7%  
Dividend payout %75.452.4 144.1%   
Avg Mkt Cap Rs m274,21622,779 1,203.8%   
No. of employees `0004.70.7 696.9%   
Total wages/salary Rs m4,8301,393 346.7%   
Avg. sales/employee Rs Th6,387.09,736.2 65.6%   
Avg. wages/employee Rs Th1,028.32,066.8 49.8%   
Avg. net profit/employee Rs Th717.1849.0 84.5%   
INCOME DATA
Net Sales Rs m30,0006,562 457.2%  
Other income Rs m728702 103.8%   
Total revenues Rs m30,7287,264 423.0%   
Gross profit Rs m4,190259 1,618.3%  
Depreciation Rs m26336 732.6%   
Interest Rs m07 0.0%   
Profit before tax Rs m4,655917 507.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,744345 505.4%   
Profit after tax Rs m3,368572 588.6%  
Gross profit margin %14.03.9 354.0%  
Effective tax rate %37.537.6 99.6%   
Net profit margin %11.28.7 128.8%  
BALANCE SHEET DATA
Current assets Rs m16,7429,731 172.0%   
Current liabilities Rs m7,2021,830 393.5%   
Net working cap to sales %31.8120.4 26.4%  
Current ratio x2.35.3 43.7%  
Inventory Days Days5249 106.4%  
Debtors Days Days2125 82.6%  
Net fixed assets Rs m8,63557 15,096.5%   
Share capital Rs m847141 602.0%   
"Free" reserves Rs m19,2229,056 212.3%   
Net worth Rs m20,0699,196 218.2%   
Long term debt Rs m100-   
Total assets Rs m30,03811,499 261.2%  
Interest coverage xNM128.4-  
Debt to equity ratio x00-  
Sales to assets ratio x1.00.6 175.0%   
Return on assets %11.25.0 222.5%  
Return on equity %16.86.2 269.7%  
Return on capital %25.510.1 253.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m528129 409.6%   
Fx outflow Rs m7,1931,734 414.8%   
Net fx Rs m-6,665-1,605 415.3%   
CASH FLOW
From Operations Rs m2,360-380 -621.9%  
From Investments Rs m3,0084,208 71.5%  
From Financial Activity Rs m-5,108-3,318 153.9%  
Net Cashflow Rs m260510 51.0%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 75.0 67.6%  
Indian inst/Mut Fund % 10.2 2.0 510.0%  
FIIs % 23.8 1.6 1,487.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 21.5 71.6%  
Shareholders   102,036 41,647 245.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   J.B.CHEMICALS  SUVEN LIFE  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare GSK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

ABBOTT INDIA at All Time High; BSE HEALTHCARE Index Down 0.7%

Jun 22, 2018 | Updated on Jun 22, 2018

ABBOTT INDIA share price has hit an all time high at Rs 7,420 (up 1.67%). The BSE HEALTHCARE Index is down by 0.74%. Among the top gainers in the BSE HEALTHCARE Index today are ABBOTT INDIA (up 1.67%) and GSK PHARMA (up 0.01%). The top losers include PFIZER (down 0.00%) and IPCA LABS (down 0.01%).

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jun 22, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - IPCA LABS COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS